Literature DB >> 27049779

Inpatient Rehabilitation after Liver Transplantation Decreases Risk and Severity of 30-Day Readmissions.

Anai N Kothari1, Ryan M Yau2, Robert H Blackwell3, Colleen Schaidle-Blackburn4, Talar Markossian5, Matthew A C Zapf1, Amy D Lu1, Paul C Kuo6.   

Abstract

BACKGROUND: Discharge location is associated with short-term readmission rates after hospitalization for several medical and surgical diagnoses. We hypothesized that discharge location: home, home health, skilled nursing facility (SNF), long-term acute care (LTAC), or inpatient rehabilitation, independently predicted the risk of 30-day readmission and severity of first readmission after orthotopic liver transplantation. STUDY
DESIGN: We performed a retrospective cohort review using Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases for Florida and California. Patients who underwent orthotopic liver transplantation from 2009 to 2011 were included and followed for 1 year. Mixed-effects logistic regression was used to model the effect of discharge location on 30-day readmission controlling for demographic, socioeconomic, and clinical factors. Total cost of first readmission was used as a surrogate measure for readmission severity and resource use.
RESULTS: A total of 3,072 patients met our inclusion criteria. The overall 30-day readmission rate was 29.6%. Discharge to inpatient rehabilitation (adjusted odds ratio [aOR] 0.43, p = 0.013) or LTAC/SNF (aOR 0.63, p = 0.014) were associated with decreased odds of 30-day readmission when compared with home. The severity of 30-day readmissions for patients discharged to inpatient rehabilitation were the same as those discharged home or home with home health. Severity was increased for those discharged to LTAC/SNF. The time to first readmission was longest for patients discharged to inpatient rehabilitation (17 days vs 8 days, p < 0.001).
CONCLUSIONS: When compared with other locations of discharge, inpatient rehabilitation reduces the risk of 30-day readmission and increases the time to first readmission. These benefits come without increasing the severity of readmission. Increased use of inpatient rehabilitation after orthotopic liver transplantation is a strategy to improve 30-day readmission rates.
Copyright © 2016 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27049779      PMCID: PMC5105886          DOI: 10.1016/j.jamcollsurg.2016.01.061

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  23 in total

1.  Clinical factors predicting readmission after orthotopic liver transplantation.

Authors:  Arema A Pereira; Renuka Bhattacharya; Robert Carithers; Jorge Reyes; James Perkins
Journal:  Liver Transpl       Date:  2012-09       Impact factor: 5.799

2.  Are all readmissions the same?

Authors:  Daniela P Ladner; Anton I Skaro; Michael M Abecassis
Journal:  Liver Transpl       Date:  2012-09       Impact factor: 5.799

3.  Reducing the length of stay for acute hospital patients needing admission into inpatient rehabilitation: a multicentre study of process barriers.

Authors:  P W New; N Andrianopoulos; P A Cameron; J H Olver; J U Stoelwinder
Journal:  Intern Med J       Date:  2013-09       Impact factor: 2.048

4.  Hospital readmission in persons with stroke following postacute inpatient rehabilitation.

Authors:  K J Ottenbacher; J E Graham; A J Ottenbacher; J Lee; S Al Snih; A Karmarkar; T Reistetter; G V Ostir
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-02       Impact factor: 6.053

5.  Risk factors for first-year hospital readmission after liver transplantation.

Authors:  Peixian Chen; Wentao Wang; Lunan Yan; Jiayin Yang; Tianfu Wen; Bo Li; Jichun Zhao; Mingqing Xu
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-05       Impact factor: 2.566

6.  Hospital readmission after a pancreaticoduodenectomy: an emerging quality metric?

Authors:  Zachary J Kastenberg; John M Morton; Brendan C Visser; Jeffrey A Norton; George A Poultsides
Journal:  HPB (Oxford)       Date:  2012-09-24       Impact factor: 3.647

7.  Hospital utilization and consequences of readmissions after liver transplantation.

Authors:  Flavio Paterno; Gregory C Wilson; Koffi Wima; Ralph C Quillin; Daniel E Abbott; Madison C Cuffy; Tayyab S Diwan; Tiffany Kaiser; E Steve Woodle; Shimul A Shah
Journal:  Surgery       Date:  2014-10       Impact factor: 3.982

8.  Predictors of Early Hospitalization After Deceased Donor Liver Transplantation.

Authors:  Jessica Yu; Amy Hosmer; Tamara Parks; Christopher J Sonnenday; Pratima Sharma
Journal:  Dig Dis Sci       Date:  2015-06-30       Impact factor: 3.199

9.  Early readmission of elderly patients with congestive heart failure.

Authors:  J M Vinson; M W Rich; J C Sperry; A S Shah; T McNamara
Journal:  J Am Geriatr Soc       Date:  1990-12       Impact factor: 5.562

10.  Variation by center and economic burden of readmissions after liver transplantation.

Authors:  Gregory C Wilson; Richard S Hoehn; Audrey E Ertel; Koffi Wima; R Cutler Quillin; Sam Hohmann; Flavio Paterno; Daniel E Abbott; Shimul A Shah
Journal:  Liver Transpl       Date:  2015-07       Impact factor: 5.799

View more
  3 in total

1.  Potential savings in the treatment pathway of liver transplantation: an inter-sectorial analysis of cost-rising factors.

Authors:  Lena Harries; Jill Gwiasda; Zhi Qu; Harald Schrem; Christian Krauth; Volker Eric Amelung
Journal:  Eur J Health Econ       Date:  2018-07-26

2.  Identifying and mitigating factors contributing to 30-day hospital readmission in high risk patient populations.

Authors:  Michael P Rogers; Paul C Kuo
Journal:  Ann Transl Med       Date:  2021-11

3.  Thirty-day readmission rates, trends and its impact on liver transplantation recipients: a national analysis.

Authors:  Khalid Mumtaz; Jannel Lee-Allen; Kyle Porter; Sean Kelly; James Hanje; Lanla F Conteh; Anthony J Michaels; Ashraf El-Hinnawi; Ken Washburn; Sylvester M Black; Marwan S Abougergi
Journal:  Sci Rep       Date:  2020-11-06       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.